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osting by EAbstract Background and objective: The promotion of therapeutic adherence is considered as an
integral component of pharmaceutical care practice and patient healthcare. It has been shown that
despite effective methods of treatment, 50% of diabetic patients fail to achieve satisfactory glycemic
control, which leads to accelerated development of complications and increased mortality. Clinical
experience indicates that no improvement of metabolic control is possible without patients’ adher-
ence to medications. This study sought to examine the rate of medication adherence and different
factors affecting it among Type 2 diabetic patients in Egypt.
Methods: A total of 226 Type 2 diabetic patients who fulﬁlled the inclusion criteria were recruited
in the current study. Adherence to the treatment was evaluated during patients’ hospitalization in
the Outpatient Clinics of Internal Medicine Department at University of Mansoura, Egypt. The
medication adherence has been assessed during a personal interview with each patient using a multi-
ple-choice graded questionnaire.of Oman, Muscat-Muttrah-Al
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226 M.E.E. Shams, E.A.M.E. BarakatResults: In the study population, the adherence rates to medication, dietary/exercise and appoint-
ment were observed to be suboptimal. The most important social factors that were signiﬁcantly
affecting adherence rate to the prescribed oral hypoglycemic agent(s) included marital status
(P< 0.01), family support (P< 0.01), and socio-economical level (P< 0.01). Other patient factors
that were signiﬁcantly affecting therapeutic adherence were patient knowledge about the disease
(P< 0.01), patients’ beliefs and motivation about prescribed drugs (P< 0.01), and regularity of
patients’ self monitoring of blood glucose level (P< 0.01). Among drug factors which found to
affect signiﬁcantly the rate of medication adherence are the number of drugs taken (P< 0.05), com-
plexity of drug regimen (P< 0.01), and the presence of drug side effects (P< 0.01). Economical
factor played an equally important role. Direct and indirect care costs in relation to patients’
income were signiﬁcantly affecting the rate of adherence to medication (P< 0.01).
Conclusions: An improvement with the adherence to oral hypoglycemic agent(s) may be achieved
through continuing patient education about diabetes, improvement of patients’ economical levels as
well as a reduction in the cost of medication. Pharmaceutical companies have to be involved and
pharmacists have to be payed for helping chronically ill patients to take their medicines correctly
for improving clinical outcomes.
ª 2010 King Saud University. All rights reserved.1. Introduction
Diabetes mellitus (DM) is one of the most common noncom-
municable diseases, and its epidemic proportion has placed it
at the forefront of public health challenges currently facing
the world (WHO, 2003). In the Eastern Mediterranean Region,
there has been a rapid increase in the incidence of DM, consist-
ing mainly of Type 2 (T2DM). Much of this increase occurs in
developing countries and results from population ageing, un-
healthy diet, obesity and a sedentary lifestyle. It is now the
fourth leading cause of death in this region (Diabetes atlas,
2003). Despite of the advances in understanding of the disease
and its management, the morbidity and mortality rate are in
rise (Paulose, 2000; Rickles et al., 2010). Non-adherence or
non-compliance, poverty, lack of knowledge and poor follow
ups are the main factors observed in poor glycemic control
(Kalyango et al., 2008). Individuals with poor management
of diabetes are at a greater risk of developing long-term micro-
and macro-vascular complications that lead to the damage of
end organs such as kidney, heart, brain and eyes, affects the di-
rect and indirect health care costs and overall quality of life
(Maddigan et al., 2005). Optimal glucose control can be
achieved through strict adherence to medications, diet, and life
style modiﬁcations that in turn minimizes long-term complica-
tions (Schectman-Joel et al., 2002; Rickles et al., 2010).
Around a quarter of patients do not take their medicines as
prescribed. The promotion of medication adherence is an
important component of pharmaceutical care practice (Arun
et al., 2008). Medication adherence or the older term, drug
compliance, is deﬁned as the extent to which a person’s medi-
cation use behavior coincides with medical or health advice;
and persistence as the duration of time from initiation to dis-
continuation of therapy (Cramer et al., 2008). For patients
with T2DM, ‘‘behavior’’ is taking oral hypoglycemic agents
(OHAs) and/or insulin injections, following diets, performing
home blood glucose monitoring and making several lifestyle
changes (Odegard and Capoccia, 2007). It has been demon-
strated that only about 50% of T2DM patients comply with
long-term treatment (Donnan et al., 2002).
After several decades of research, it was concluded that
medication non-adherence is due to many factors including
lack of adequate knowledge about medication and treatmentgoals, beliefs about the medication, complex regimens that
are difﬁcult to manage, side effects, and costs associated with
medications (Martin et al., 2005; Osterberg and Blaschke,
2005). There are several types of non-adherence. Therapeutic
or medication non-adherence which includes failure to have
the prescription dispensed or renewed, omission of doses, er-
rors of dosage, incorrect administration, errors in the time
and frequency of administration, and premature discontinua-
tion of the drug regimen. A second type of non-adherence is
dietary/exercise non-adherence in which the patient fails to fol-
low the diet and exercise recommendations. A third type is the
appointment non-adherence in which the patient fails to show
up at the clinics for the scheduled check up (Clark and For-
well, 2000). The consequences of medication non-adherence
may not only be dangerous for patient’s health, but also dra-
matically increase the ﬁnancial costs of public health services
(Muszbek et al., 2008). The healthcare providers, inclusive of
physician, pharmacist (hospital and community pharmacists),
and nurses play an equally important role in achieving patient
adherence to diabetic treatment regimens (Vermeire et al.,
2005).
Several methods are used to measure therapeutic adher-
ence. Indirect methods, like self reports and interviews with
patient, are the simplest and most common methods for mea-
suring medication adherence (Girerd et al., 2001). Pill counts
method is also used to assess medication adherence in medical
drug trials, by measuring the difference between the number of
doses initially dispensed and the number remaining in the con-
tainer (Rudd et al., 1998). The achievement of treatment goals
might also be used to assess medication adherence, especially
when the drug therapy is associated with a successful outcome
like normal blood glucose levels. Computerized compliance
monitors are the most recent and reliable methods, like the
Medication Event Monitoring System (MEMS). The system
consists of microprocessor placed in the cap of the medication
container, every time the patient removes the cap; the time and
date are recorded. Other modern technology is the mobile
computing and communications technology embodied in the
modern cell phone device which can be employed to improve
the lives of diabetes patients by giving them better tools for
self-management and improving the rate of medication adher-
ence (Hedtke, 2008). Direct methods of measuring therapeutic
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markers in the patients’ biological ﬂuids, could also be used
(Liu et al., 2002).
Few studies about patient adherence to OHAs in Arab
Countries have been published. Most of these studies were
carried out in Saudi Arabia. One study was performed at
Al-Manhal primary health care center, aimed at identifying
determinants of compliance among diabetic patients attending
that clinic (Khattab et al., 1999). Other study has been con-
ducted in Palestine aiming to study the effect of ‘‘polyphar-
macy’’ and ‘‘frequency of drug dosing’’ on the rate of
compliance among diabetic and hypertensive patients (Sweileh
et al., 2003). The third study was performed to study the rate
of compliance among patients with DM and hypertension
(Sweileh et al., 2005). A recent study was performed to gather
data on current practices in the management of patients with
T2DM in Saudi Arabia and to evaluate the degree of compli-
ance with international guidelines (Al-Elq, 2009). Of the vari-
ous methods available for assessing compliance, self reports
and interviews with patients were the simplest and most com-
mon methods for measuring medication adherence (Girerd
et al., 2001). On the other hand, it is established that adherence
rates to treatment are bad in chronic illnesses. Nevertheless,
data on medication adherence among diabetics are scarce (Be-
ziea et al., 2006). The studies so far have generally evaluated
medication adherence and its effects on metabolic control of
diabetes, while factors affecting medication adherence itself
have been analyzed less frequently (Schectman-Joel et al.,
2002). For the previous reasons and due to the limited body
of evidence regarding this important health and economic issue
in the Egyptian population, we conducted this research study
whose aim was to investigate the variability in the rate of med-
ication adherence among Type 2 diabetic patients. This may
lead to a clear understanding about poor glycemic control
among these patients as well as for a strict and successful man-
agement of this chronic illness in the future.
2. Materials and methods
2.1. Patients’ characteristics
From November 2007 to March 2008, a total 226 patients were
recruited in the current study. These patients were randomly
selected from the Outpatient Clinics of Internal Medicine
Department at Specialized Medical Hospital at University of
Mansoura, Egypt. No patient was repeated. Patients’ consent
was obtained according to the regulations of the Ministry of
Health in Egypt. Patients were informed that personal infor-
mation will never be disclosed to a third party.
Inclusion criteria for all participants were: patients P18
years of age, who had been diagnosed with T2DM at least 1
year earlier, who received oral hypoglycemic medication
(sulphonylurea or/and biguanide), who did not use insulin or
suffer from chronic complications, and consented to partici-
pate in the study.
2.2. Assessment of medication adherence
The adherence was assessed during a personal interview with
each patient using a structured questionnaire addressing the
following aspects: (i) socio-demographic patient proﬁle; (ii)
level of knowledge about diabetes mellitus disease and itscomplications; (iii) access to and use of medicines, patients’
beliefs and motivation about OHA(s), patient-health care
provider relationship, regularity of monitoring of blood glu-
cose level, number of drug taken, drug regimen, experience
side effects, and direct and indirect care costs in relation
to patient income; (iv) assessment of patient adherence to
medication using the Measure Treatment Adherence
(MTA) Scale developed by Delgado and Lima (2001). This
method was used before more frequently to measure patient
compliance with drug treatment (Lopes et al., 2008). The
MTA Scale, a variation of the Morisky-Green Test with
seven questions, was used to assess patient behavior patterns
associated with the use of medicines (Morisky et al., 1986).
The MTA Scale consists of the following questions: (1)
Have you ever forgotten to take your medicines? (2) Were
you careless at times about taking your medicines? (3) When
you felt better, did you sometimes stop taking your medi-
cines? (4) Sometimes, if you felt worse, did you stop taking
your medicines? (6) Have you ever discontinued treatment
because you ran out of pills? (7) Have you ever stopped tak-
ing your medicines for any reason other than a medical
advisory? The MTA Scale allows answers from ‘‘always’’
to ‘‘never,’’ with scores ranging from 1 to 4 points. The
highest values indicate the highest level of compliance with
drug treatment; (v) assessment of patient adherence to diet
restrictions, exercise, and appointment for regular checkup
in the clinics. All questions were read to the participant,
and the answers were recorded by a pharmacist or a physi-
cian. Patients collecting more than 75% of the highest
points were considered in the good adherence group.
Patients collecting less than 50% of the points were consid-
ered in the non-adherence group and ﬁnally patients collect-
ing between 50% and 75% of the points were considered in
the poor/partial adherence group.2.3. Data management and statistical analysis
Computer software GraphPad InStat version 3.00, GraphPad
Software, San Diego, California, USA was used to analyze the
data obtained from the questionnaire. Chi-square test and con-
tingency coefﬁcient test were used to analyze the signiﬁcant
correlations between adherence rate and the tested factors.
For certain two variables, when P value is less than 0.05, there
is a statistically signiﬁcant relationship between the two
variables.
3. Results
From a total of 417 patients who were clinically examined
during the study period in the Department of Internal
Medicine in Specialized Medical Hospital, Mansoura Uni-
versity, Mansoura, Egypt, only 226 patients (54.2%) fulﬁlled
the inclusion criteria within the study period. The social
characteristics of the selected group of patients and their
demographic data are summarized in Table 1.
Several factors were found to have signiﬁcant effects on the
rate of medication adherence (Table 2).
The overall rate of medication adherence, dietary/exercise
adherence, and appointment adherence among the patients
population was found to be suboptimal and non-acceptable
(Fig. 1).
Table 1 A correlation between patients’ socio-demographic characteristics and adherence rate to treatment with oral hypoglycemic
agents.
Variables N (%) Number of patients (%) in diﬀerent categories Chi-square P value
226 (100) Good
adherence
(N= 88)
Fair/poor
adherence
(N= 101)
Non-adherence
(N= 37)
Gender
Male 129 (57.1) 42 (32.5) 63 (48.8) 24 (18.7) 5.214 0.07
Female 97 (42.9) 46 (47.5) 38 (39.1) 13 (13.4)
Age (years)
Young group (18–40) 56 (24.8) 29 (51.8) 23 (41.1) 4 (7.1) 7.981 0.09
Middle-age group (41–60) 138 (61.0) 50 (36.2) 62 (44.9) 26 (18.9)
Elderly group (P60) 32 (14.2) 9 (28.1) 16 (50.0) 7 (21.9)
Marital status
Single/widowed/divorced 82 (36.3) 18 (21.9) 42 (51.2) 22 (26.8) 19.361 <0.01**
Married 144 (63.7) 70 (48.6) 59 (41.0) 15 (10.4)
Educational status
No formal education (illiterate/basic) 29 (12.8) 7 (24.1) 14 (48.3) 8 (27.6) 5.492 0.24
School level education (middle level) 81 (35.8) 30 (37.0) 38 (47.0) 13 (16.0)
University level education or more (high level) 116 (51.4) 51 (43.9) 49 (42.2) 16 (13.85)
Family support
Present 134 (59.3) 64 (47.7) 51 (38.1) 19 (14.2) 10.786 <0.01**
Absent 92 (40.7) 24 (26.1) 50 (54.4) 18 (19.5)
Socio-economical level
High 12 (5.3) 8 (66.6) 2(16.6) 2(16.6) 21.389 <0.01**
Middle 58 (25.7) 34 (58.6) 15 (25.8) 9 (15.6)
Low 156 (69.0) 46 (29.4) 84 (53.8) 26 (16.6.)
Place of residence
City 136 (60.1) 57 (41.9) 61(44.8) 18 (13.2) 2.830 0.243
Village 90 (39.9) 31 (34.4) 40 (44.4) 19 (23.3)
*Signiﬁcance difference between good, poor and non-adherence categories according to different variables at (P< 0.05 using Chi-square test).
** High signiﬁcance difference at (P< 0.01).
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Poor adherence to medication seems to be a signiﬁcant barrier
to attainment of positive clinical or therapeutic outcomes
among Type 2 diabetic patients in both developed and devel-
oping countries (Adisa et al., 2009). It has been reported that,
in general, diabetic patients are non-adherent to their treat-
ment and only a small number of diabetic patients were found
adherent or compliant with all aspects of diabetic care (Kurtz,
1990). This is in agreement with the current research study as it
was noted that only 38.9%, 21.1% and 18.4% of all patients
were belonging to the good category of adherence to drug, die-
tary/exercise and to the appointment for regular fellow up,
respectively. The others were ranging between the poor to
the non-adherence categories. Unfortunately, there is no pub-
lished data yet regarding adherence to OHAs in Egypt in order
to compare with these results.
Our results have also shown that therapeutic adherence
was signiﬁcantly affected by different patient-centered fac-
tors like marital status, family support, socio-economical le-
vel, patients’ knowledge about the diabetes mellitus disease,
patients’ beliefs and motivation about OHAs, and patient
self monitoring of blood glucose level. Also, it was shown
that drug-related factors like number of medication therapy
taken, complexity of drug regimen, presence of drug side
effects, and ﬁnally cost of treatment signiﬁcantly affectthe rate of adherence to OHAs. On the other hand, a
non-signiﬁcant higher rate of medication was found in fe-
males than in males.
Married patients showed signiﬁcant higher rate of thera-
peutic adherence (48.6%) than single, widowed or divorced
ones (21.9%). Marital status might inﬂuence patients’ compli-
ance with medication positively. The help and support from a
spouse could be the reason why married patients were more
compliant to medication than single patients (Cooper et al.,
2005).
The effect of the education factor on the degree of adher-
ence to medication was not surprising in our patient popula-
tion. More educated people tend to appreciate and
understand the consequences of non-adherence. Thus the de-
gree of adherence was increased but none signiﬁcantly with
increasing level of education. Illiterate patients cannot read
or distinguish their medications which increase the risk of er-
rors and nonadherence. Illiteracy might negatively affect pa-
tients’ medical knowledge (Sweileh et al., 2005).
Support provided by family also played a beneﬁcial role in
enhancing adherence (Kasznicki et al., 2007). The general ﬁnd-
ings from different research articles showed that patients who
had emotional support and help from family members, or
healthcare providers were more likely to be adherent to the
treatment (Seol and Min, 2005; Voils et al., 2005). The social
support helps patients in reducing negative attitudes to treat-
Table 2 Factors affecting rate of medication adherence in Type 2 diabetic patients.
Variables N (%) Number of patients (%) in diﬀerent categories Chi-square P value
226 (100) Good adherence (N= 88) Fair/Poor adherence (N= 101) Non-adherence (N= 37)
Patient knowledge
Rich/adequate 86 (38.0) 46 (53.5) 22 (25.6) 18 (20.9) 20.654 <0.01**
Poor 140 (62.0) 42 (30.0) 79 (56.4) 19 (13.6)
Patients’ beliefs and motivation about OHAs
Good 101 (44.7) 64 (63.3) 25 (24.8) 12 (11.9) 46.477 <0.01**
Weak 125 (55.3) 24 (19.2) 76 (60.8) 25 (20.0)
Patient-health care provider relationship
Good communication 132 (58.4) 59 (44.7) 55 (41.7) 18 (13.6) 4.803 0.09
Poor communication 94 (41.6) 29 (30.9) 46 (48.9) 19 (20.2)
Monitoring of blood glucose level
Regular 65 (28.7) 43 (66.1) 15 (23.1) 7 (10.7) 28.643 <0.01**
Irregular 161 (71.3) 45 (27.9) 86 (53.5) 30 (18.6)
Number of drug taken
Monotherapy 87 (38.5) 41 (47.1) 39 (44.8) 7 (8.1) 9.340 <0.05*
Combination therapy 46 (22.3) 16 (34.8) 22 (47.9) 8 (17.3)
Polypharmacy 93 (41.2) 31 (33.3) 40 (43.1) 22 (23.6)
Drug regimen
Complex 118 (52.2) 31 (26.3) 56 (47.5) 31(26.2) 16.665 <0.01**
Simple 108 (47.8) 57 (52.8) 33 (30.6) 18 (16.6)
Experience side eﬀects
Present 137 (60.6.) 38 (27.7) 74 (54.1) 25 (18.2) 18.725 <0.01**
Absent 89(39.4) 50 (56.1) 27 (30.4) 12 (13.5)
Direct and indirect care cost s in relation to patient income
Adequate 97 (42.9) 56 (57.7) 32 (33.0) 9 (9.3) 25.844 <0.01**
Inadequate 129 (57.1) 32 (24.8) 69(53.5) 28 (21.7)
* Signiﬁcance difference between good, poor and non-adherence categories according to different variables at (P< 0.05 using Chi-square test).
** High signiﬁcance difference at (P< 0.01).
Figure 1 Overall adherence rate among Type 2 diabetic patients.
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treatment as well.
The effect of age and gender were obvious but also non-sig-
niﬁcant in our results. The effect of gender on the rate of
adherence to medication in other research studies is contradic-
tory. Female patients were found by some researchers to have
better adherence (Lertmaharit et al., 2005), while some studies
suggested otherwise (Hertz et al., 2005). In addition, some
studies could not ﬁnd a relationship between gender and
adherence to medication (Senior et al., 2004).Moreover, a non-signiﬁcant lower rate of drug compliance
was found in elderly patients (28.1%) and middle-aged group
(36.2%) than younger group of patients (51.8%). With increas-
ing age, the degree of adherence decreases for several reasons.
For example, most of the elderly patients have memory prob-
lems related to age or due to dementia or Alzheimer’s disease.
Furthermore, most elderly patients have vision and hearing
problems that might increase the potential of mistakes in tak-
ing medications. Another problem with elderly is that most of
them have several diseases and take several drugs at the same
230 M.E.E. Shams, E.A.M.E. Barakattime which might be confusing to most elderly patient. These
general characteristics are common among elderly patients in
most societies and that is why similar ﬁndings were made in
other countries by other researchers (Norell, 1985; Sweileh
et al., 2005).
Our results conﬁrm that one of the most important factor
contributing to adherence to OHAs was the level of patients’
knowledge about the disease, its causes, principles of drug
therapy and complications of drug therapy as well as patients’
beliefs and motivation about OHAs. Patients who had low
motivation to change behaviors or take medication are be-
lieved to have poor compliance (Spikmans et al., 2003).
Patient’s knowledge about their disease and treatment is
not always adequate. Some patients lack understanding of
the role their therapies play in the treatment (Ponnusankar
et al., 2004); others lack knowledge about the disease and con-
sequences of poor adherence (Gascon et al., 2004); or lack
understanding of the value of clinic visits (Lawson et al.,
2005). Some patients thought that the need for medication
was intermittent, so they stopped the drug to see whether med-
ication was still needed (Bender and Bender, 2005). For these
reasons, patient education is very important to enhance adher-
ence to OHAs.
A healthy relationship is based on patients’ trust in pre-
scribers and empathy from the prescribers, pharmacists and
nurses. Studies have found that adherence to medication is
good when healthcare providers are emotionally supportive,
giving reassurance or respect, and treating patients as an equal
partner (Lawson et al., 2005).
Self management behavior with emphasis on regular mon-
itoring of blood glucose found to be low (28.7%) among our
patients population. Many of our diabetes patients were not
aware of self monitoring of blood glucose level at home
(SMBG) or lack ﬁnancial support to buy the apparatus for
regular and prompt detection of ﬂuctuations in their blood
glucose levels. This ﬁnding was in conformity with the report
of a study in US where many diabetes patients in US were
reported never to have monitored their blood glucose levels
(Harris et al., 1993). The absence of established guidelines on
SMBG and lack of its perceived importance by patients, as
well as, the cost of the blood glucose monitoring device espe-
cially in a developing country like Egypt, may have accounted
for the low level of awareness among patients. Though practice
of SMBG does not necessarily mean that patient is adherent
with prescribed treatment recommendations but it may be an
indication of active commitment of patient to his/her diabetes
management.
The results also showed clearly an inverse relationship be-
tween the rate of adherence to OHAs and the number of drug
therapy in patient’s population. The rate of non-adherence
jumps from 8.1% to 17.3% and 23.6 % when the number of
medications is increased from one oral OHA (sulphonylurea
or biguanide) to two drugs for treatment of diabetes (combina-
tion therapy like a sulphonylurea with a biguanide) or more
than two for treatment of diabetes and other disease problems
(polypharmacy like T2DM and hypertension), respectively.
These results are in agreement with the ﬁndings in other re-
search study (Sweileh et al., 2003).
Complex treatment is believed to threaten the patient’s
compliance. Our results showed that the rate of adherence to
OHAs was increased from (26.3%) in patients who took multi-
ple daily dosing (MDD) to the double (52.8%) in patients whotook once daily dosing (ODD) indicating that in Type 2 dia-
betic patients, once daily dosing is the best. This is in agree-
ment with the ﬁndings of other researchers who found that
the rate of compliance decreased as the number of daily doses
increased (Iskedjian et al., 2002). Thus, simplifying the medica-
tion dosing frequency could improve the adherence markedly.
Side effects of OHAs like loss of appetite, nausea, diarrhea
and intestinal discomfort were mentioned by our diabetic
patients and were considered as a part of the factors contribut-
ing to medication nonadherence. This conﬁrmed the ﬁndings
in the literature that reported that the side effects of medica-
tion may be a signiﬁcant factor that can affect diabetes pa-
tients’ long-term adherence to treatment programs (Jayant
et al., 2000).
A signiﬁcant higher rate of adherence to OHAs (57.7%)
was observed in patients who exhibited adequate healthcare
costs in relation to their income or full coverage health insur-
ance compared with the others who did not have (24.8%).
Financial variables especially the direct and indirect costs asso-
ciated with a prescribed regimen and restricted access to ther-
apy have been found by several studies to inﬂuence patients’
commitment to medication adherence in developing countries
(Ohene-Buabeng et al., 2004; Adisa et al., 2009). A number
of studies found that patients who had no insurance cover
(Kaplan et al., 2004; Choi-Kwon et al., 2005), or who had
low income (Mishra et al., 2005) were more likely to be non-
adherent to treatment.
Aerobic exercise and restricted food was reported to be part
of the recommended non-drug management of diabetes melli-
tus disease (Hensrud, 2001). It was obvious from our results
that the rate of non-adherence to appointment for regular
checkup of the patients at clinics is much higher (54.4%) than
non-adherence to dietary restriction and applying aerobic exer-
cise (28.3%) and to medication (15.9%). The overall adherence
to medication, diet restriction/aerobic exercise and to appoint-
ment was found to be suboptimal. These results were also ob-
served in other research studies (Spikmans et al., 2003).
5. Conclusions
Our study population of patients with T2DM has demon-
strated unsatisfactory adherence to OHAs, dietary/exercise
and even appointment to show up at the clinics for the sched-
uled check up. An improvement with medication adherence
may be achieved through continuing patient education about
the disease, improvement of patients’ socio-economical levels,
encouraging patients to monitor their blood glucose level reg-
ularly, simplifying drug regimen with decreasing the number of
drug taken as can as possible as well as reducing in the medi-
cation cost which is considered as a new strategy of Ministry of
Health in Egypt nowadays. This strategy aimed to optimize
medication costs for the majority of chronically ill patients
and this may give a sound regarding adherence to medication
in the near future. Our recommendations for future works are
to use validated adherence measures, e.g., Medication Adher-
ence Reports Scale (MARS) and to run other methods concur-
rently for assessment of therapeutic adherence, e.g., pill counts
for a comparison study. Moreover, it is very important to con-
duct a research on a larger sample population and from differ-
ent clinical settings and areas but this will require a good
budget for a ﬁnancial support. Further research studies should
emphasize the importance of effective patient-health care pro-
Measuring the rate of therapeutic adherence amongoutpatients with T2DM in Egypt 231vider communication in overcoming some of the barriers to
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